{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:47:11Z","timestamp":1792806431665,"version":"4.5.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":1970,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s13311-018-0621-8","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T10:38:30Z","timestamp":1524047910000},"page":"313-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5390-819X","authenticated-orcid":false,"given":"Till","family":"Sprenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tassorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-018-0621-8_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1741-7015-7-71","article-title":"Migraine pathogenesis and state of pharmacological treatment options","volume":"7","author":"Sprenger","year":"2009","journal-title":"BMC Med"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/head.12999","article-title":"Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies","volume":"57","author":"Aurora","year":"2017","journal-title":"Headache"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nm0202-136","article-title":"Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model","volume":"8","author":"Bolay","year":"2002","journal-title":"Nat Med"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1468-2982.2008.01713.x","article-title":"Are cortical spreading depression and headache in migraine causally linked?","volume":"29","author":"Wolthausen","year":"2009","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1007\/s13311-018-0621-8_bib5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1586\/14737175.2013.835587","article-title":"Is the migrainous brain normal outside of acute attacks? Lessons learned from psychophysical, neurochemical and functional neuroimaging studies","volume":"13","author":"Niazi","year":"2013","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1474-4422(10)70005-3","article-title":"Current practice and future directions in the prevention and acute management of migraine","volume":"9","author":"Goadsby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1007\/s13311-018-0621-8_bib7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","article-title":"EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force","volume":"16","author":"Evers","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-018-0621-8_bib8","article-title":"[Relaxation techniques and behavioural therapy for the treatment of migraine : guidelines from the German Migraine and Headache Society].","author":"Kropp","year":"2017","journal-title":"Schmerz"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/head.13069","article-title":"An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine","volume":"57","author":"Puledda","year":"2017","journal-title":"Headache"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ana.20778","article-title":"Suppression of cortical spreading depression in migraine prophylaxis","volume":"59","author":"Ayata","year":"2006","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10194-011-0300-1","article-title":"Protection of flunarizine on cerebral mitochondria injury induced by cortical spreading depression under hypoxic conditions","volume":"12","author":"Li","year":"2011","journal-title":"J Headache Pain"},{"issue":"46","key":"10.1007\/s13311-018-0621-8_bib13","doi-asserted-by":"crossref","first-page":"18985","DOI":"10.1073\/pnas.1215435109","article-title":"Critical role of calcitonin gene-related peptide receptors in cortical spreading depression","volume":"109","author":"Tozzi","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 4","key":"10.1007\/s13311-018-0621-8_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2006.01648.x","article-title":"The structure and mode of action of different botulinum toxins","volume":"13","author":"Dolly","year":"2006","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.1007\/s13311-018-0621-8_bib15","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1097\/j.pain.0000000000001007","article-title":"Propranolol treatment prevents chronic central sensitization induced by repeated dural stimulation","volume":"158","author":"Boyer","year":"2017","journal-title":"Pain"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","article-title":"OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine","volume":"156","author":"Cernuda-Morollon","year":"2015","journal-title":"Pain"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2009.04.019","article-title":"Prophylactic drugs and cytokine and leptin levels in children with migraine","volume":"41","author":"Hirfanoglu","year":"2009","journal-title":"Pediatr Neurol"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2007.04.060","article-title":"Cardiovascular protection using beta-blockers: a critical review of the evidence","volume":"50","author":"Bangalore","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.0306-5251.2001.01459.x","article-title":"The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers","volume":"52","author":"Limmroth","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 5","key":"10.1007\/s13311-018-0621-8_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/03331024860060S502","article-title":"Efficacy of beta-blockers in migraine. A critical review","volume":"6","author":"Tfelt-Hansen","year":"1986","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1526-4610.2007.00785.x","article-title":"Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?","volume":"48","author":"Schellenberg","year":"2008","journal-title":"Headache"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1468-2982.1997.1705596.x","article-title":"Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study","volume":"17","author":"van de Ven","year":"1997","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-2006-939919","article-title":"Prophylactic pharmacotherapy for migraine headaches","volume":"26","author":"Buchanan","year":"2006","journal-title":"Semin Neurol"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-3565(25)30125-4","article-title":"Induction of tyrosine hydroxylase elicited by beta adrenergic receptor agonists in normal and decentralized sympathetic ganglia: role of cyclic 3\u2032,5\u2032 - adenosine monophosphate","volume":"193","author":"Hanbauer","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"issue":"2\u20133","key":"10.1007\/s13311-018-0621-8_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0031-6865(99)00030-8","article-title":"Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics","volume":"74","author":"Hieble","year":"2000","journal-title":"Pharm Acta Helv"},{"key":"10.1007\/s13311-018-0621-8_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainres.2008.01.023","article-title":"Labetalol facilitates GABAergic transmission to rat periaqueductal gray neurons via antagonizing beta1-adrenergic receptors--a possible mechanism underlying labetalol-induced analgesia","volume":"1198","author":"Xiao","year":"2008","journal-title":"Brain Res"},{"issue":"Suppl","key":"10.1007\/s13311-018-0621-8_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00543711","article-title":"CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action","volume":"28","author":"Koella","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1007\/s13311-018-0621-8_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/03331024860060S501","article-title":"Migraine and beta-blockade: modulation of sympathetic neurotransmission.","volume":"6","author":"Ablad","year":"1986","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1007\/s13311-018-0621-8_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0024-3205(94)00546-X","article-title":"Is migraine prophylactic activity caused by 5-HT2B or 5-HT2C receptor blockade?","volume":"54","author":"Kalkman","year":"1994","journal-title":"Life Sci"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib30","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.53.7.1473","article-title":"Increased brain serotonin synthesis in migraine","volume":"53","author":"Chugani","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11916-004-0022-z","article-title":"Prophylactic migraine therapy: mechanisms and evidence","volume":"8","author":"Ramadan","year":"2004","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ana.410250204","article-title":"Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials","volume":"25","author":"Diener","year":"1989","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1526-4610.2000.00005.x","article-title":"Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials","volume":"40","author":"Sandor","year":"2000","journal-title":"Headache"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0006-3223(93)90137-3","article-title":"Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis","volume":"33","author":"Hegerl","year":"1993","journal-title":"Biol Psychiatry"},{"issue":"9","key":"10.1007\/s13311-018-0621-8_bib35","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1468-2982.2007.01377.x","article-title":"Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study","volume":"27","author":"Siniatchkin","year":"2007","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib36","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/89522","article-title":"A neural circuit for circadian regulation of arousal","volume":"4","author":"Aston-Jones","year":"2001","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-0173(03)00143-7","article-title":"The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain research","volume":"42","author":"Berridge","year":"2003","journal-title":"Brain Res Rev"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/BF00169175","article-title":"Effects of antimigraine drugs on retinal spreading depression","volume":"353","author":"Wiedemann","year":"1996","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"9","key":"10.1007\/s13311-018-0621-8_bib39","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/sj.jcbfm.9600120","article-title":"Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage","volume":"25","author":"Richter","year":"2005","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000117004","article-title":"Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat","volume":"34","author":"Kaube","year":"1994","journal-title":"Eur Neurol"},{"issue":"Pt 1","key":"10.1007\/s13311-018-0621-8_bib41","first-page":"86","article-title":"Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?","volume":"128","author":"Shields","year":"2005","journal-title":"Brain J Neurol"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib42","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/01.wnl.0000297551.27191.70","article-title":"Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study","volume":"70","author":"Silberstein","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib43","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/0333102410388433","article-title":"Oxcarbazepine does not suppress cortical spreading depression","volume":"31","author":"Hoffmann","year":"2011","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"10.1007\/s13311-018-0621-8_bib44","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1046\/j.1526-4610.2001.01154-2.x","article-title":"Antiepileptic drugs: how they work in headache","volume":"41","author":"Cutrer","year":"2001","journal-title":"Headache"},{"issue":"2\u20133","key":"10.1007\/s13311-018-0621-8_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eplepsyres.2005.01.001","article-title":"Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase","volume":"63","author":"Shank","year":"2005","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1007\/s13311-018-0621-8_bib46","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1526-4610.2006.00538.x","article-title":"Repression of stimulated calcitonin gene-related peptide secretion by topiramate","volume":"46","author":"Durham","year":"2006","journal-title":"Headache"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib47","first-page":"153","article-title":"Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide","volume":"65","author":"Garcia-Estevez","year":"2017","journal-title":"Rev Neurol"},{"issue":"6","key":"10.1007\/s13311-018-0621-8_bib48","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1046\/j.1471-4159.1994.63062361.x","article-title":"Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro","volume":"63","author":"Chen","year":"1994","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-018-0621-8_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s10194-016-0631-z","article-title":"Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-small ka, CyrillicB","volume":"17","author":"Li","year":"2016","journal-title":"J Headache Pain"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib50","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1526-4610.1985.hed2507368.x","article-title":"Comparative efficacy of calcium antagonist drugs in the prophylaxis of migraine","volume":"25","author":"Solomon","year":"1985","journal-title":"Headache"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib51","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neulet.2010.10.064","article-title":"Flunarizine blocks voltage-gated Na(+) and Ca(2+) currents in cultured rat cortical neurons: a possible locus of action in the prevention of migraine","volume":"487","author":"Ye","year":"2011","journal-title":"Neurosci Lett"},{"issue":"17","key":"10.1007\/s13311-018-0621-8_bib52","first-page":"2649","article-title":"Flunarizine inhibits sensory neuron excitability by blocking voltage-gated Na+ and Ca2+ currents in trigeminal ganglion neurons.","volume":"124","author":"Ye","year":"2011","journal-title":"Chin Med J"},{"issue":"10","key":"10.1007\/s13311-018-0621-8_bib53","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.4088\/JCP.v69n1007","article-title":"Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia","volume":"69","author":"Bisol","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1007\/s13311-018-0621-8_bib54","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1468-2982.2005.00956.x","article-title":"Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment","volume":"25","author":"Berilgen","year":"2005","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib55","doi-asserted-by":"crossref","first-page":"e0130733","DOI":"10.1371\/journal.pone.0130733","article-title":"A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache","volume":"10","author":"Jackson","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1526-4610.2005.05029.x","article-title":"The efficacy and safety of venlafaxine in the prophylaxis of migraine","volume":"45","author":"Ozyalcin","year":"2005","journal-title":"Headache"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-2999(99)00464-1","article-title":"Do alpha2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds?","volume":"378","author":"Gray","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib58","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1073\/pnas.94.5.2036","article-title":"Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac)","volume":"94","author":"Ni","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib59","doi-asserted-by":"crossref","first-page":"250","DOI":"10.9758\/cpn.2016.14.3.250","article-title":"Association of polymorphisms within the serotonin receptor genes 5-HTR1A, 5-HTR1B, 5-HTR2A and 5-HTR2C and migraine susceptibility in a Turkish population","volume":"14","author":"Yucel","year":"2016","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib60","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1526-4610.2006.00624.x","article-title":"Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study","volume":"47","author":"Aurora","year":"2007","journal-title":"Headache"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib61","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1526-4610.2007.00963.x","article-title":"Botulinum toxin type A in the treatment of chronic migraine without medication overuse","volume":"48","author":"Freitag","year":"2008","journal-title":"Headache"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","article-title":"Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial","volume":"45","author":"Mathew","year":"2005","journal-title":"Headache"},{"issue":"6","key":"10.1007\/s13311-018-0621-8_bib63","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1526-4610.2000.00066.x","article-title":"Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.","volume":"40","author":"Silberstein","year":"2000","journal-title":"Headache"},{"issue":"9","key":"10.1007\/s13311-018-0621-8_bib64","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4065\/80.9.1126","article-title":"Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Silberstein","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib65","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib66","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1007\/s13311-018-0621-8_bib67","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib68","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","article-title":"From poison to remedy: the chequered history of botulinum toxin","volume":"115","author":"Erbguth","year":"2008","journal-title":"J Neural Transm"},{"issue":"10","key":"10.1007\/s13311-018-0621-8_bib69","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1007\/s13311-018-0621-8_bib70","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1524-4725.1998.tb04098.x","article-title":"Treatment of hyperfunctional lines of the face with botulinum toxin A","volume":"24","author":"Binder","year":"1998","journal-title":"Dermatol Surg"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib71","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1468-2982.2006.01114.x","article-title":"Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study","volume":"26","author":"Silberstein","year":"2006","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib72","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1468-2982.2004.00641.x","article-title":"Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study","volume":"24","author":"Ondo","year":"2004","journal-title":"Cephalalgia"},{"issue":"16","key":"10.1007\/s13311-018-0621-8_bib73","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2012.505","article-title":"Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis","volume":"307","author":"Jackson","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"10.1007\/s13311-018-0621-8_bib74","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00115-016-0138-5","article-title":"Botulinum toxin type A in headache treatment: established and experimental indications","volume":"87","author":"Gaul","year":"2016","journal-title":"Nervenarzt"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1756285616677005","article-title":"Botulinum toxin in the management of chronic migraine: clinical evidence and experience","volume":"10","author":"Escher","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib76","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","article-title":"Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A","volume":"26","author":"Aoki","year":"2005","journal-title":"Neurotoxicology"},{"issue":"11","key":"10.1007\/s13311-018-0621-8_bib77","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"10.1007\/s13311-018-0621-8_bib78","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","article-title":"Evidence for antinociceptive activity of botulinum toxin type A in pain management","volume":"43","author":"Aoki","year":"2003","journal-title":"Headache"},{"key":"10.1007\/s13311-018-0621-8_bib79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/nyas.12488","article-title":"Development of onabotulinumtoxinA for chronic migraine","volume":"1329","author":"Whitcup","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","article-title":"The origin, structure, and pharmacological activity of botulinum toxin","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharmacol Rev"},{"issue":"6442","key":"10.1007\/s13311-018-0621-8_bib81","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/365160a0","article-title":"Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25","volume":"365","author":"Blasi","year":"1993","journal-title":"Nature"},{"issue":"11","key":"10.1007\/s13311-018-0621-8_bib82","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.pain.2013.07.041","article-title":"Anti-nociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type A","volume":"154","author":"Mustafa","year":"2013","journal-title":"Pain"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib83","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0854.2006.00520.x","article-title":"Traffic of botulinum toxins A and E in excitatory and inhibitory neurons","volume":"8","author":"Verderio","year":"2007","journal-title":"Traffic"},{"issue":"6","key":"10.1007\/s13311-018-0621-8_bib84","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00702-013-1150-6","article-title":"Association of antinociceptive action of botulinum toxin type A with GABA-A receptor","volume":"121","author":"Drinovac","year":"2014","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib85","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/BF01941714","article-title":"Inhibition by tetanus and botulinum A toxin of the release of [3H]noradrenaline and [3H]GABA from rat brain homogenate","volume":"44","author":"Habermann","year":"1988","journal-title":"Experientia"},{"key":"10.1007\/s13311-018-0621-8_bib86","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.parkreldis.2011.06.013","article-title":"Updates on the antinociceptive mechanism hypothesis of botulinum toxin A.","volume":"17","author":"Aoki","year":"2011","journal-title":"Parkinsonism & related disorders."},{"issue":"1\u20132","key":"10.1007\/s13311-018-0621-8_bib87","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pain.2008.10.005","article-title":"Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin","volume":"141","author":"Gazerani","year":"2009","journal-title":"Pain"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib88","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pain.2006.04.014","article-title":"The effects of Botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization","volume":"122","author":"Gazerani","year":"2006","journal-title":"Pain"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib89","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cne.22049","article-title":"Sensory innervation of the calvarial bones of the mouse","volume":"515","author":"Kosaras","year":"2009","journal-title":"J Comp Neurol"},{"issue":"9","key":"10.1007\/s13311-018-0621-8_bib90","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.pain.2013.04.040","article-title":"Extracranial projections of meningeal afferents and their impact on meningeal nociception and headache","volume":"154","author":"Schueler","year":"2013","journal-title":"Pain"},{"issue":"6","key":"10.1007\/s13311-018-0621-8_bib91","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/head.12371","article-title":"Innervation of rat and human dura mater and pericranial tissues in the parieto-temporal region by meningeal afferents","volume":"54","author":"Schueler","year":"2014","journal-title":"Headache"},{"issue":"9","key":"10.1007\/s13311-018-0621-8_bib92","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0333102416636843","article-title":"Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle?","volume":"36","author":"Zhang","year":"2016","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1007\/s13311-018-0621-8_bib93","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00109-008-0331-5","article-title":"Brain renin angiotensin in disease","volume":"86","author":"Phillips","year":"2008","journal-title":"J Mol Med"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib94","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.hjh.0000220419.86149.11","article-title":"Involvement of the renin-angiotensin system in migraine.","volume":"24","author":"Tronvik","year":"2006","journal-title":"Journal of hypertension supplement : official journal of the International Society of Hypertension."},{"issue":"7277","key":"10.1007\/s13311-018-0621-8_bib95","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.322.7277.19","article-title":"Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study","volume":"322","author":"Schrader","year":"2001","journal-title":"BMJ"},{"issue":"3 Pt 2","key":"10.1007\/s13311-018-0621-8_bib96","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00004872-200103001-00011","article-title":"Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury","volume":"19","author":"Ito","year":"2001","journal-title":"J Hypertens"},{"issue":"6","key":"10.1007\/s13311-018-0621-8_bib97","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0143-4179(85)90116-7","article-title":"Naloxone reverses the effects of enalapril and enalaprilic acid on the pressor responses to afferent vagal stimulation","volume":"6","author":"Montastruc","year":"1985","journal-title":"Neuropeptides"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0361-9230(98)00039-2","article-title":"Angiotensin receptors in the nervous system","volume":"47","author":"Allen","year":"1998","journal-title":"Brain Res Bull"},{"issue":"3\u20134","key":"10.1007\/s13311-018-0621-8_bib99","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10571-005-4011-5","article-title":"Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities","volume":"25","author":"Saavedra","year":"2005","journal-title":"Cell Mol Neurobiol"},{"issue":"10","key":"10.1007\/s13311-018-0621-8_bib100","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1161\/01.STR.31.10.2478","article-title":"Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats","volume":"31","author":"Nishimura","year":"2000","journal-title":"Stroke"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib101","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.10159","article-title":"Nuclear factor-kappaB as a molecular target for migraine therapy","volume":"51","author":"Reuter","year":"2002","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib102","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1681\/ASN.V1351162","article-title":"Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice","volume":"13","author":"Lorenzo","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib103","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1468-2982.2002.00396.x","article-title":"The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study","volume":"22","author":"Pfaffenrath","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-018-0621-8_bib104","first-page":"CD002286","article-title":"Feverfew for preventing migraine","volume":"1","author":"Pittler","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1007\/s13311-018-0621-8_bib105","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1468-2982.2005.00950.x","article-title":"Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention\u2014a randomized, double-blind, multicentre, placebo-controlled study","volume":"25","author":"Diener","year":"2005","journal-title":"Cephalalgia"},{"issue":"6495","key":"10.1007\/s13311-018-0621-8_bib106","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/bmj.291.6495.569","article-title":"Efficacy of feverfew as prophylactic treatment of migraine","volume":"291","author":"Johnson","year":"1985","journal-title":"Br Med J"},{"issue":"8","key":"10.1007\/s13311-018-0621-8_bib107","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1468-2982.2005.00915.x","article-title":"Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine","volume":"25","author":"Tassorelli","year":"2005","journal-title":"Cephalalgia"},{"issue":"12","key":"10.1007\/s13311-018-0621-8_bib108","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1016\/j.pain.2013.08.002","article-title":"Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel","volume":"154","author":"Materazzi","year":"2013","journal-title":"Pain"},{"issue":"10","key":"10.1007\/s13311-018-0621-8_bib109","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1111\/bph.12512","article-title":"The TRPA1 channel in migraine mechanism and treatment","volume":"171","author":"Benemei","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"1\u20133","key":"10.1007\/s13311-018-0621-8_bib110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0378-8741(99)00115-4","article-title":"Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats","volume":"68","author":"Jain","year":"1999","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"10.1007\/s13311-018-0621-8_bib111","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.2042-7158.1990.tb07057.x","article-title":"A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro","volume":"42","author":"Groenewegen","year":"1990","journal-title":"J Pharm Pharmacol"},{"issue":"12","key":"10.1007\/s13311-018-0621-8_bib112","first-page":"1106","article-title":"5-Hydroxytryptamine-inhibiting property of Feverfew: role of parthenolide content","volume":"21","author":"Mittra","year":"2000","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib113","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11916-006-0020-4","article-title":"Is serotonin hyperalgesic or analgesic?","volume":"10","author":"Sommer","year":"2006","journal-title":"Curr Pain Headache Rep"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib114","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1046\/j.1526-4610.1998.3807534.x","article-title":"Plasticity of 5-HT serotonin receptor in patients with analgesic-induced transformed migraine","volume":"38","author":"Srikiatkhachorn","year":"1998","journal-title":"Headache"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib115","first-page":"303","article-title":"An extract of Petasites hybridus is effective in the prophylaxis of migraine","volume":"6","author":"Grossman","year":"2001","journal-title":"Alternative medicine review: a journal of clinical therapeutic"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib116","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000076535","article-title":"The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria","volume":"51","author":"Diener","year":"2004","journal-title":"Eur Neurol"},{"issue":"12","key":"10.1007\/s13311-018-0621-8_bib117","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1212\/01.WNL.0000147290.68260.11","article-title":"Petasites hybridus root (butterbur) is an effective preventive treatment for migraine","volume":"63","author":"Lipton","year":"2004","journal-title":"Neurology"},{"issue":"9\u201310","key":"10.1007\/s13311-018-0621-8_bib118","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.phymed.2006.02.008","article-title":"Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine: a systematic review","volume":"13","author":"Agosti","year":"2006","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib119","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-2005-837744","article-title":"Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42\/44 MAP kinase activation in rat primary microglial cells","volume":"71","author":"Fiebich","year":"2005","journal-title":"Planta Med"},{"issue":"8","key":"10.1007\/s13311-018-0621-8_bib120","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0006-2952(01)00552-4","article-title":"Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridus","volume":"61","author":"Thomet","year":"2001","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib121","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-2999(02)01764-8","article-title":"Ca2+ channel blocking effect of iso-S-petasin in rat aortic smooth muscle cells","volume":"445","author":"Wang","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib122","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/s-2003-37711","article-title":"The mechanism of inhibitory actions of S-petasin, a sesquiterpene of Petasites formosanus, on L-type calcium current in NG108-15 neuronal cells","volume":"69","author":"Wu","year":"2003","journal-title":"Planta Med"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib123","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0022-3565(24)29533-1","article-title":"Calcium channel blockade in vascular smooth muscle cells: major hypotensive mechanism of S-petasin, a hypotensive sesquiterpene from Petasites formosanus.","volume":"297","author":"Wang","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib124","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.50.2.466","article-title":"Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial","volume":"50","author":"Schoenen","year":"1998","journal-title":"Neurology"},{"issue":"7","key":"10.1007\/s13311-018-0621-8_bib125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1468-1331.2004.00813.x","article-title":"High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre","volume":"11","author":"Boehnke","year":"2004","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-018-0621-8_bib126","first-page":"223","article-title":"Oral riboflavin versus oral propranolol in migraine prophylaxis: an open label randomized controlled trial","volume":"16","author":"Nambiar","year":"2011","journal-title":"Neurol Asia"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib127","first-page":"334","article-title":"Riboflavin. Monograph.","volume":"13","year":"2008","journal-title":"Altern Med Rev."},{"issue":"21","key":"10.1007\/s13311-018-0621-8_bib128","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1001\/jamainternmed.2013.10391","article-title":"Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis","volume":"173","author":"Meissner","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2174\/13892029113149990007","article-title":"Studies on the pathophysiology and genetic basis of migraine","volume":"14","author":"Gasparini","year":"2013","journal-title":"Curr Genomics"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"issue":"1\u20132","key":"10.1007\/s13311-018-0621-8_bib131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0022-510X(95)00196-1","article-title":"Mitochondria, magnesium and migraine","volume":"134","author":"Welch","year":"1995","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib132","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0361-9230(01)00440-3","article-title":"Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache","volume":"54","author":"Lodi","year":"2001","journal-title":"Brain Res Bull"},{"issue":"8","key":"10.1007\/s13311-018-0621-8_bib133","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.58.8.1227","article-title":"Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes","volume":"58","author":"Boska","year":"2002","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib134","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1526-4610.1993.hed3303135.x","article-title":"Deficiency in serum ionized magnesium but not total magnesium in patients with migraines. Possible role of ICa2+\/IMg2+ ratio","volume":"33","author":"Mauskop","year":"1993","journal-title":"Headache"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1468-2982.1992.1201021.x","article-title":"Serum and salivary magnesium levels in migraine and tension-type headache. Results in a group of adult patients.","volume":"12","author":"Sarchielli","year":"1992","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1007\/s13311-018-0621-8_bib136","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1526-4610.2004.04098_2.x","article-title":"Magnesium therapy for migraine: do we need more trials or more reflection?","volume":"44","author":"Gupta","year":"2004","journal-title":"Headache"},{"issue":"6","key":"10.1007\/s13311-018-0621-8_bib137","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1526-4610.2003.03102.x","article-title":"Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial","volume":"43","author":"Wang","year":"2003","journal-title":"Headache"},{"issue":"2","key":"10.1007\/s13311-018-0621-8_bib138","first-page":"101","article-title":"The effects of magnesium prophylaxis in migraine without aura","volume":"21","author":"Koseoglu","year":"2008","journal-title":"Magnes Res"},{"issue":"1\u20133","key":"10.1007\/s13311-018-0621-8_bib139","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12011-012-9487-5","article-title":"The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis","volume":"150","author":"Tarighat Esfanjani","year":"2012","journal-title":"Biol Trace Elem Res"},{"issue":"4","key":"10.1007\/s13311-018-0621-8_bib140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1468-2982.1996.1604257.x","article-title":"Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study","volume":"16","author":"Peikert","year":"1996","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1007\/s13311-018-0621-8_bib141","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1468-2982.1996.1606436.x","article-title":"Magnesium in the prophylaxis of migraine\u2014a double-blind placebo-controlled study","volume":"16","author":"Pfaffenrath","year":"1996","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1007\/s13311-018-0621-8_bib142","first-page":"888","article-title":"Menstrually related migraine: breaking the cycle in your clinical practice","volume":"52","author":"Silberstein","year":"2007","journal-title":"J Reprod Med"},{"issue":"3","key":"10.1007\/s13311-018-0621-8_bib143","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1526-4610.2011.01847.x","article-title":"Nutraceuticals and headache: the biological basis","volume":"51","author":"Taylor","year":"2011","journal-title":"Headache"},{"issue":"1","key":"10.1007\/s13311-018-0621-8_bib144","first-page":"24","article-title":"Role of magnesium in the pathogenesis and treatment of migraines","volume":"5","author":"Mauskop","year":"1998","journal-title":"Clin Neurosci"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-018-0621-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0621-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923015635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923015635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0621-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:07:54Z","timestamp":1761808074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923015635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1878747923015635"],"URL":"https:\/\/doi.org\/10.1007\/s13311-018-0621-8","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-018-0621-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}